Batavia Biosciences focuses on accelerating the transition of biopharmaceutical
product candidates from discovery to the clinic with improved success and
Hereto, the company has developed a portfolio of technologies aimed to improve product
yield (STEP®), reduce process development time (SIDUS®, SCOUT®) and increase product
stability. These technologies have amply demonstrated to improve speed and reduce
cost in biopharmaceutical development, accelerating the journey from bench to clinic.
Equipped to tackle challenges
The company employs a highly educated staff with many years of experience in DNA
cloning, mammalian cell line generation, upstream process development (mammalian,
microbial & insect cell platforms), purification development, product characterization,
and clinical manufacturing. As such the company, with laboratories in USA and the
Netherlands, is well positioned to take on any challenge associated with the development
of complex biological medicines be it proteins, antibodies, vaccines or viral vectors.
Batavia Biosciences aims to significantly contribute to ease human suffering from disease
by improving the success rate in the translation of candidate biopharmaceutical
medicines from discovery to the clinic.
Batavia Biosciences actively develops know-how and technologies to support global
health initiatives and the biopharmaceutical industry to bring new and improved
medicines to the market.